Diabetes remission in drug‐naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study
Authors' conclusion
In drug-naïve patients with T2D, dorzagliatin treatment leads to stable glycaemic control and drug-free diabetes remission. Improvements in β-cell function and TIR in these patients are important contributors to diabetes remission.
Study context
- Population
- Drug-naïve patients with T2D who completed dorzagliatin treatment in the SEED trial and achieved stable glycaemic control
- Outcome
- Diabetes remission probability (Kaplan-Meier)
- Follow-up
- Week 52
Methodological detailssingle-group, post hoc sensitivity analysis
- Single-group
- Post hoc sensitivity analysis
Main finding
As reported in the abstract
Kaplan-Meier diabetes remission probability
Kaplan-Meier remission probability at week 52
65.2%
95% CI 52.0%, 75.6%
Observational data: associations, not effects.
Further findings
Remission probability by American Diabetes Association (ADA) definition (post hoc sensitivity analysis) · week 12
- Remission probability, ADA definition, at week 12
- 52.0% (95% CI: 31.2%, 69.2%)
- Post hoc sensitivity analysis
Changes during SEED trial associated with drug-free remission
- Improvement in insulin secretion index ΔC30/ΔG30 (P = .0238)
- 41.46 ± 77.68
- Improvement in disposition index (P = .0030)
- 1.22 ± 1.65
- Improvement in HOMA2-β (P < .0001)
- 11.49 ± 14.58
- Improvement in HOMA2-IR (P = .0130)
- −0.16 ± 0.36
Time in range (TIR) during SEED trial
- TIR improved from 60% to more than 80%; estimated treatment difference
- 23.8% (95% CI: 7.3%, 40.2%; P = .0084)
Original publication
Diabetes remission in drug‐naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study. Diabetes Obes Metab. Published 29 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →